A Prospective Epidemiologic Study of ALK-Positive NSCLC in China (C-TALK)

Clinical Trial ID NCT02042105

PubWeight™ 1.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02042105

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Onco Targets Ther 2015 0.90
2 Clinical trials for lung cancer in China. Transl Lung Cancer Res 2014 0.80
Next 100